HeartLung Corporation
HeartLung Technologies utilizes AI to detect life-threatening conditions like heart disease, lung cancer, osteoporosis, and fatty liver disease from CT scans, aiming to prevent premature deaths and reduce healthcare costs. Their flagship product, AI-CVD™, analyzes scans for hidden heart risks and provides early intervention strategies. Key products include AutoBMD™ for bone density and spinal fracture detection, AutoChamber™ for identifying enlarged cardiac chambers and hypertrophy, and AI-CAC™ for coronary artery calcium scoring. The company has received FDA Breakthrough Designation and marketing authorization for AI-CVD™ and has secured CMS reimbursement for AutoChamber™. HeartLung's mission is to help people live longer by eliminating preventable deaths through early detection, partnering with healthcare providers and consumers.
HeartLung Corporation
HeartLung Technologies utilizes AI to detect life-threatening conditions like heart disease, lung cancer, osteoporosis, and fatty liver disease from CT scans, aiming to prevent premature deaths and reduce healthcare costs. Their flagship product, AI-CVD™, analyzes scans for hidden heart risks and provides early intervention strategies. Key products include AutoBMD™ for bone density and spinal fracture detection, AutoChamber™ for identifying enlarged cardiac chambers and hypertrophy, and AI-CAC™ for coronary artery calcium scoring. The company has received FDA Breakthrough Designation and marketing authorization for AI-CVD™ and has secured CMS reimbursement for AutoChamber™. HeartLung's mission is to help people live longer by eliminating preventable deaths through early detection, partnering with healthcare providers and consumers.